Back
HLS Therapeutics Inc (HLTRF) Earnings
HLTRF Stock Price Chart
HLTRF Earnings
HLS Therapeutics Inc
Latest Earnings Results: Q4 '25
Reported: 2026-03-12
Historical Earnings
Quarterly
Annual
EPS
Revenue
Earnings FAQ
How did HLTRF's recent EPS compare to expectations?
How did HLS Therapeutics Inc HLTRF's revenue perform in the last quarter?
What is the revenue estimate for HLS Therapeutics Inc?
What's the earning quality score for HLS Therapeutics Inc?
When does HLS Therapeutics Inc report earnings?
What are HLS Therapeutics Inc's expected earnings?
Did HLS Therapeutics Inc beat earnings expectations?
Key Stats
Prev.Close
$3.36
Open
$3.45
Day's Range
$3 - $3.45
52 week range
$2.73 - $4.02
Volume
600
Avg.Volume
21
Dividend yield
--
EPS (TTM)
-0.45
Market Cap
$93.8M
What is HLTRF?
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 86 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Features
Resources
© 2026 Finture Development Limited. All rights reserved